Suppr超能文献

基于超顺磁性氧化铁的磁共振成像对比剂:临床应用的现状。

Superparamagnetic iron oxide based MRI contrast agents: Current status of clinical application.

机构信息

Department of Imaging and Interventional Radiology; Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong SAR, China.

出版信息

Quant Imaging Med Surg. 2011 Dec;1(1):35-40. doi: 10.3978/j.issn.2223-4292.2011.08.03.

Abstract

Superparamagnetic iron oxide (SPIO) MR contrast agents are composed of nano-sized iron oxide crystals coated with dextran or carboxydextran. Two SPIO agents are clinically approved, namely: ferumoxides (Feridex in the USA, Endorem in Europe) with a particle size of 120 to 180 nm, and ferucarbotran (Resovist) with a particle size of about 60 nm. The principal effect of the SPIO particles is on T2* relaxation and thus MR imaging is usually performed using T2/T2*-weighted sequences in which the tissue signal loss is due to the susceptibility effects of the iron oxide core. Enhancement on T1-weighted images can also be seen with the smaller Resovist. Both Feridex and Resovist are approved specifically for MRI of the liver. The difference being that Resovist can be administered as a rapid bolus (and thus can be used with both dynamic and delayed imaging), whereas Feridex needs to be administered as a slow infusion and is used solely in delayed phase imaging. In the liver, these particles are sequestered by phagocytic Kupffer cells in normal reticuloendothelial system (RES), but are not retained in lesions lacking Kupffer cells. Consequently, there are significant differences in T2/T2* relaxation between normal tissue and lesions, resulting in increased lesion conspicuity and detectability. SPIO substantially increase the detectability of hepatic metastases. For focal hepatocellular lesions, SPIO-enhanced MR imaging exhibits slightly better diagnostic performance than dynamic CT. A combination of dynamic and static MR imaging technique using T1- and T2 imaging criteria appears to provide clinically more useful patterns of enhancement. Feridex and Resovist are also used for evaluating macrophage activities in some inflammatory lesions, but their clinical values remain to be further confirmed. The clinical development of Ferumoxtran (Combidex in the USA, Sinerem in Europe), designed for lymph node metastasis evaluation, is currently stopped.

摘要

超顺磁性氧化铁(SPIO)磁共振对比剂由纳米级氧化铁晶体与葡聚糖或羧基葡聚糖组成。有两种 SPIO 制剂已在临床上获得批准,即:粒径为 120-180nm 的 Ferumoxides(美国的 Feridex,欧洲的 Endorem)和粒径约为 60nm 的 Ferucarbotran(Resovist)。SPIO 颗粒的主要作用是影响 T2弛豫,因此磁共振成像通常使用 T2/T2-加权序列进行,其中组织信号丢失是由于氧化铁核心的磁化率效应所致。较小的 Resovist 也可以在 T1 加权图像上看到增强。Feridex 和 Resovist 均专门用于肝脏 MRI。两者的区别在于,Resovist 可以快速推注给药(因此可用于动态和延迟成像),而 Feridex 需要缓慢输注给药,仅用于延迟相成像。在肝脏中,这些颗粒被正常网状内皮系统(RES)中的吞噬性库普弗细胞隔离,但不会在缺乏库普弗细胞的病变中保留。因此,正常组织和病变之间的 T2/T2*弛豫存在显著差异,导致病变的显著性和可检测性增加。SPIO 极大地提高了肝转移瘤的检测能力。对于局灶性肝细胞病变,SPIO 增强磁共振成像显示出略优于动态 CT 的诊断性能。使用 T1 和 T2 成像标准的动态和静态磁共振成像技术的组合似乎提供了更具临床实用价值的增强模式。Feridex 和 Resovist 也用于评估某些炎症病变中的巨噬细胞活性,但它们的临床价值仍有待进一步确认。用于评估淋巴结转移的 Ferumoxtran(美国的 Combidex,欧洲的 Sinerem)的临床开发目前已停止。

相似文献

1
Superparamagnetic iron oxide based MRI contrast agents: Current status of clinical application.
Quant Imaging Med Surg. 2011 Dec;1(1):35-40. doi: 10.3978/j.issn.2223-4292.2011.08.03.
2
Application of superparamagnetic iron oxide to imaging of hepatocellular carcinoma.
Eur J Radiol. 2006 May;58(2):200-16. doi: 10.1016/j.ejrad.2005.11.040. Epub 2006 Jan 18.
7
Current status of superparamagnetic iron oxide contrast agents for liver magnetic resonance imaging.
World J Gastroenterol. 2015 Dec 21;21(47):13400-2. doi: 10.3748/wjg.v21.i47.13400.

引用本文的文献

2
Automatic design and optimization of MRI-based neurochemical sensors via reinforcement learning.
Discov Nano. 2025 Sep 1;20(1):148. doi: 10.1186/s11671-025-04338-z.
3
Stimuli-Responsive Materials for Biomedical Applications.
Adv Mater. 2025 Sep;37(36):e07559. doi: 10.1002/adma.202507559. Epub 2025 Aug 13.
4
Nickel Ferrite Nanoparticles for In Vivo Multimodal Magnetic Resonance and Magnetic Particle Imaging.
ACS Appl Nano Mater. 2025 Jul 16;8(29):14867-14881. doi: 10.1021/acsanm.5c03013. eCollection 2025 Jul 25.
6
Morphology Effect of PEGylated Iron Oxide Nanoparticles on the Enhancement of MRI Contrast Signal in Breast Cancer.
ACS Appl Mater Interfaces. 2025 Aug 6;17(31):44275-44287. doi: 10.1021/acsami.5c12013. Epub 2025 Jul 28.
8
Carbon-Encapsulated Iron Nanoparticles Seeking Integrins in Murine Glioma.
Int J Nanomedicine. 2025 Apr 28;20:5475-5488. doi: 10.2147/IJN.S511286. eCollection 2025.
10
Imaging-guided precision hyperthermia with magnetic nanoparticles.
Nat Rev Bioeng. 2025 Mar;3(3):245-260. doi: 10.1038/s44222-024-00257-3. Epub 2024 Nov 7.

本文引用的文献

7
Application of superparamagnetic iron oxide to imaging of hepatocellular carcinoma.
Eur J Radiol. 2006 May;58(2):200-16. doi: 10.1016/j.ejrad.2005.11.040. Epub 2006 Jan 18.
8
Ferucarbotran-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma.
AJR Am J Roentgenol. 2005 Apr;184(4):1069-76. doi: 10.2214/ajr.184.4.01841069.
9
Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours.
Neuropathol Appl Neurobiol. 2004 Oct;30(5):456-71. doi: 10.1111/j.1365-2990.2004.00557.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验